<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01109823</url>
  </required_header>
  <id_info>
    <org_study_id>2010/167</org_study_id>
    <nct_id>NCT01109823</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Evaluation of Fluoroquinolone Antibiotics Administered Intravenously in Intensive Care Patients With Normal Renal Function and With Renal Hyperfiltration</brief_title>
  <official_title>Pharmacokinetic Evaluation of Fluoroquinolone Antibiotics Administered Intravenously in Intensive Care Patients With Normal Renal Function and With Renal Hyperfiltration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Ghent</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      At the intensive care unit (ICU) fluoroquinolone antibiotics, like levofloxacin, are&#xD;
      frequently used for the treatment of infections.&#xD;
&#xD;
      Adequate blood levels are required for a good efficacy of the antibiotic. Due to the fact&#xD;
      that levofloxacin is almost completely eliminated renally, the blood levels for this&#xD;
      antibiotic are strongly influenced by the renal function. Therefore, this study aims to&#xD;
      evaluate the pharmacokinetics of levofloxacin in patients with hyperfiltration, in comparison&#xD;
      with critically ill patients with normal renal function.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 19, 2010</start_date>
  <completion_date type="Actual">December 1, 2013</completion_date>
  <primary_completion_date type="Actual">December 1, 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>to evaluate the pharmacokinetics of levofloxacin in patients with hyperfiltration, in comparison with critically ill patients with normal renal function.</measure>
    <time_frame>12 hours after start antibiotic treatment</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Infection</condition>
  <arm_group>
    <arm_group_label>patients with normal renal function</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with normal renal function hospitalized at the Department Intensive Care Unit who are being treated with levofloxacin I.V. (500mg, twice daily) for an infection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>patients with hyperfiltration</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with hyperfiltration hospitalized at the Department Intensive Care Unit who are being treated with levofloxacin I.V. (500mg, twice daily) for an infection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intravenous administration of levofloxacin</intervention_name>
    <description>Intravenous administration of levofloxacin is used.</description>
    <arm_group_label>patients with hyperfiltration</arm_group_label>
    <arm_group_label>patients with normal renal function</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients hospitalized at the Department Intensive Care Unit who are being treated with&#xD;
             levofloxacin I.V. (500mg, twice daily) for an infection.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Younger than 18 years&#xD;
&#xD;
          -  No informed consent&#xD;
&#xD;
          -  No arterial catheter&#xD;
&#xD;
          -  Hematocrit â‰¤ 21&#xD;
&#xD;
          -  Pregnancy and lactation&#xD;
&#xD;
          -  Creatinine clearance &lt; 80 ml/min&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Van Bocxlaer, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Ghent</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Ghent</name>
      <address>
        <city>Ghent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Ghent</name>
      <address>
        <city>Ghent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 22, 2010</study_first_submitted>
  <study_first_submitted_qc>April 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2010</study_first_posted>
  <last_update_submitted>June 23, 2021</last_update_submitted>
  <last_update_submitted_qc>June 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Patients hospitalized at Intensive Care Unit treated with levofloxacin IV</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

